Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent

Gillian W. Reierson, Claudio A. Mastronardi, Julio Licinio, Ma Li Wong

Research output: Contribution to journalArticle

Abstract

Circadian rhythm disturbances can occur as part of the clinical symptoms of major depressive disorder and have been found to resolve with antidepressant therapy. The pineal gland is relevant to circadian rhythms as it secretes the hormone melatonin following activation of the cyclic adenosine monophosphate (cAMP) signaling cascade and of arylalkylamine N-acetyltransferase (AA-NAT), the rate-limiting enzyme for its synthesis. Cyclic AMP is synthesized by adenylate cyclases (AC) and degraded by phosphodiesterases (PDEs). Little is known about the contribution of the PDE system to antidepressant-induced alterations in pineal cAMP signaling and melatonin synthesis. In the present study we used enzyme immunoassay to measure plasma melatonin levels and pineal cAMP levels and as well as quantitative real-time polymerase chain reaction to measure pineal expression of PDE, AC, and AA-NAT genes in rats chronically treated with the prototypic antidepressant fluoxetine. We found elevated melatonin synthesis with increased pineal AA-NAT gene expression and daytime plasma melatonin levels and downregulated cAMP signaling with increased PDE and unchanged AC pineal gene expression, and decreased content of pineal cAMP. We conclude that chronic fluoxetine treatment increases daytime plasma melatonin and pineal AA-NAT gene expression despite downregulated pineal cAMP signaling in the rodent.

LanguageEnglish
Pages1-6
Number of pages6
JournalClinical Pharmacology: Advances and Applications
Volume1
Issue number1
Publication statusPublished - 2009
Externally publishedYes

Keywords

  • Antidepressant
  • Cyclic
  • Melatonin
  • Nucleotides
  • Phosphodiesterase
  • Pineal
  • Rat

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Reierson, G. W., Mastronardi, C. A., Licinio, J., & Wong, M. L. (2009). Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent. Clinical Pharmacology: Advances and Applications, 1(1), 1-6.
Reierson, Gillian W. ; Mastronardi, Claudio A. ; Licinio, Julio ; Wong, Ma Li. / Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent. In: Clinical Pharmacology: Advances and Applications. 2009 ; Vol. 1, No. 1. pp. 1-6.
@article{032b706d93d742cd8583524be0ed1422,
title = "Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent",
abstract = "Circadian rhythm disturbances can occur as part of the clinical symptoms of major depressive disorder and have been found to resolve with antidepressant therapy. The pineal gland is relevant to circadian rhythms as it secretes the hormone melatonin following activation of the cyclic adenosine monophosphate (cAMP) signaling cascade and of arylalkylamine N-acetyltransferase (AA-NAT), the rate-limiting enzyme for its synthesis. Cyclic AMP is synthesized by adenylate cyclases (AC) and degraded by phosphodiesterases (PDEs). Little is known about the contribution of the PDE system to antidepressant-induced alterations in pineal cAMP signaling and melatonin synthesis. In the present study we used enzyme immunoassay to measure plasma melatonin levels and pineal cAMP levels and as well as quantitative real-time polymerase chain reaction to measure pineal expression of PDE, AC, and AA-NAT genes in rats chronically treated with the prototypic antidepressant fluoxetine. We found elevated melatonin synthesis with increased pineal AA-NAT gene expression and daytime plasma melatonin levels and downregulated cAMP signaling with increased PDE and unchanged AC pineal gene expression, and decreased content of pineal cAMP. We conclude that chronic fluoxetine treatment increases daytime plasma melatonin and pineal AA-NAT gene expression despite downregulated pineal cAMP signaling in the rodent.",
keywords = "Antidepressant, Cyclic, Melatonin, Nucleotides, Phosphodiesterase, Pineal, Rat",
author = "Reierson, {Gillian W.} and Mastronardi, {Claudio A.} and Julio Licinio and Wong, {Ma Li}",
year = "2009",
language = "English",
volume = "1",
pages = "1--6",
journal = "Clinical Pharmacology: Advances and Applications",
issn = "1179-1438",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

Reierson, GW, Mastronardi, CA, Licinio, J & Wong, ML 2009, 'Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent', Clinical Pharmacology: Advances and Applications, vol. 1, no. 1, pp. 1-6.

Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent. / Reierson, Gillian W.; Mastronardi, Claudio A.; Licinio, Julio; Wong, Ma Li.

In: Clinical Pharmacology: Advances and Applications, Vol. 1, No. 1, 2009, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent

AU - Reierson, Gillian W.

AU - Mastronardi, Claudio A.

AU - Licinio, Julio

AU - Wong, Ma Li

PY - 2009

Y1 - 2009

N2 - Circadian rhythm disturbances can occur as part of the clinical symptoms of major depressive disorder and have been found to resolve with antidepressant therapy. The pineal gland is relevant to circadian rhythms as it secretes the hormone melatonin following activation of the cyclic adenosine monophosphate (cAMP) signaling cascade and of arylalkylamine N-acetyltransferase (AA-NAT), the rate-limiting enzyme for its synthesis. Cyclic AMP is synthesized by adenylate cyclases (AC) and degraded by phosphodiesterases (PDEs). Little is known about the contribution of the PDE system to antidepressant-induced alterations in pineal cAMP signaling and melatonin synthesis. In the present study we used enzyme immunoassay to measure plasma melatonin levels and pineal cAMP levels and as well as quantitative real-time polymerase chain reaction to measure pineal expression of PDE, AC, and AA-NAT genes in rats chronically treated with the prototypic antidepressant fluoxetine. We found elevated melatonin synthesis with increased pineal AA-NAT gene expression and daytime plasma melatonin levels and downregulated cAMP signaling with increased PDE and unchanged AC pineal gene expression, and decreased content of pineal cAMP. We conclude that chronic fluoxetine treatment increases daytime plasma melatonin and pineal AA-NAT gene expression despite downregulated pineal cAMP signaling in the rodent.

AB - Circadian rhythm disturbances can occur as part of the clinical symptoms of major depressive disorder and have been found to resolve with antidepressant therapy. The pineal gland is relevant to circadian rhythms as it secretes the hormone melatonin following activation of the cyclic adenosine monophosphate (cAMP) signaling cascade and of arylalkylamine N-acetyltransferase (AA-NAT), the rate-limiting enzyme for its synthesis. Cyclic AMP is synthesized by adenylate cyclases (AC) and degraded by phosphodiesterases (PDEs). Little is known about the contribution of the PDE system to antidepressant-induced alterations in pineal cAMP signaling and melatonin synthesis. In the present study we used enzyme immunoassay to measure plasma melatonin levels and pineal cAMP levels and as well as quantitative real-time polymerase chain reaction to measure pineal expression of PDE, AC, and AA-NAT genes in rats chronically treated with the prototypic antidepressant fluoxetine. We found elevated melatonin synthesis with increased pineal AA-NAT gene expression and daytime plasma melatonin levels and downregulated cAMP signaling with increased PDE and unchanged AC pineal gene expression, and decreased content of pineal cAMP. We conclude that chronic fluoxetine treatment increases daytime plasma melatonin and pineal AA-NAT gene expression despite downregulated pineal cAMP signaling in the rodent.

KW - Antidepressant

KW - Cyclic

KW - Melatonin

KW - Nucleotides

KW - Phosphodiesterase

KW - Pineal

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=77953446568&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 1

EP - 6

JO - Clinical Pharmacology: Advances and Applications

T2 - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

SN - 1179-1438

IS - 1

ER -